{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:01:05Z","timestamp":1781805665024,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cardiovascular Revascularization Medicine"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.carrev.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T02:36:53Z","timestamp":1746844613000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial"],"prefix":"10.1016","volume":"83","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaohan","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingbao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuncheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohai","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.carrev.2025.05.007_bb0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nrcardio.2017.18","article-title":"Antithrombotic therapy for patients with STEMI undergoing primary PCI","volume":"14","author":"Franchi","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.carrev.2025.05.007_bb0010","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0140-6736(17)31936-0","article-title":"Update on antithrombotic therapy after percutaneous coronary revascularisation","volume":"390","author":"Cuisset","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2025.05.007_bb0015","first-page":"2045","article-title":"Associations between dual anti-platelet therapy score and long-term mortality after percutaneous coronary intervention: analysis of >27,000 patients","volume":"40","author":"Tan","year":"2024","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.carrev.2025.05.007_bb0020","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2025.05.007_bb0025","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis","volume":"122","author":"Steg","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2025.05.007_bb0030","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2025.05.007_bb0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.05.007_bb0040","first-page":"766","article-title":"2019 Chinese Society of Cardiology (CSC) guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction","volume":"47","year":"2019","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"10.1016\/j.carrev.2025.05.007_bb0045","first-page":"697","article-title":"Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study","volume":"11","author":"Godtfredsen","year":"2022","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.carrev.2025.05.007_bb0050","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012447","article-title":"Sex-specific differences in potent P2Y(12) inhibitor use in British Cardiovascular Intervention Society Registry STEMI patients","volume":"16","author":"Burgess","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.05.007_bb0055","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.carrev.2025.05.007_bb0060","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","article-title":"Bivalirudin vs heparin anticoagulation in STEMI: confirmation of the BRIGHT-4 results","volume":"84","author":"Stone","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.carrev.2025.05.007_bb0065","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ehjqcco\/qcac018","article-title":"Transradial versus transfemoral approach for percutaneous coronary intervention in patients with ST-elevation myocardial infarction complicated by cardiogenic shock: a systematic review and meta-analysis","volume":"8","author":"Ahsan","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.carrev.2025.05.007_bb0070","first-page":"777","article-title":"Transradial vs Transfemoral percutaneous coronary intervention in ST-segment elevation myocardial infarction: a systemic review and Meta-analysis","volume":"32","author":"Singh","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.carrev.2025.05.007_bb0075","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/CD9.0000000000000068","volume":"2","author":"Liang","year":"2022","journal-title":"Cardiology Discovery."},{"key":"10.1016\/j.carrev.2025.05.007_bb0080","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2025.05.007_bb0085","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.carrev.2025.05.007_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.carrev.2025.05.007_bb0095","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/heartjnl-2015-308963","article-title":"Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention","volume":"102","author":"Velders","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.carrev.2025.05.007_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcin.2022.10.023","article-title":"Timing, selection, modulation, and duration of P2Y(12) inhibitors for patients with acute coronary syndromes undergoing PCI","volume":"16","author":"Capodanno","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.05.007_bb0105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.mayocp.2023.02.004","article-title":"Contemporary use of Ticagrelor vs Clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GRACE risk score stratification-based analysis in a large-scale, real-world study from China","volume":"98","author":"Qiu","year":"2023","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.carrev.2025.05.007_bb0110","first-page":"8","article-title":"Access and non-access site bleeding after percutaneous coronary intervention and risk of subsequent mortality and major adverse cardiovascular events: systematic review and meta-analysis","author":"Kwok","year":"2015","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.carrev.2025.05.007_bb0115","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/CD9.0000000000000016","article-title":"Bivalirudin in primary PCI: can its glory being restored?","volume":"1","author":"Li","year":"2021","journal-title":"Cardiology Discovery"},{"key":"10.1016\/j.carrev.2025.05.007_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031606","article-title":"Review of the Ticagrelor trials evidence base","volume":"13","author":"Herron","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.carrev.2025.05.007_bb0125","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.carrev.2025.05.007_bb0130","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.carrev.2025.05.007_bb0135","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/joic.12058","article-title":"A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching","volume":"26","author":"Delalls","year":"2013","journal-title":"J Interv Cardiol"},{"key":"10.1016\/j.carrev.2025.05.007_bb0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17425255.2023.2178895","article-title":"Pharmacogenomics in Asians: differences and similarities with other human populations","volume":"19","author":"Biswas","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Cardiovascular Revascularization Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925002350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1553838925002350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:15:36Z","timestamp":1771499736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1553838925002350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"alternative-id":["S1553838925002350"],"URL":"https:\/\/doi.org\/10.1016\/j.carrev.2025.05.007","relation":{},"ISSN":["1553-8389"],"issn-type":[{"value":"1553-8389","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ticagrelor vs. clopidogrel in bivalirudin-treated patients with STEMI undergoing primary PCI: The BRIGHT-4 trial","name":"articletitle","label":"Article Title"},{"value":"Cardiovascular Revascularization Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.carrev.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}